Tailored antiplatelet secondary prevention in non-cardioembolic ischemic stroke: a phase IV gender-stratified randomized controlled trial (TAILOR trial)
Key facts
- Where
- Bologna, Cesena és Modena, OlaszországSee the 3 sites
- Phase
- 4. fázis
Where in Olaszország
- Azienda Unita Sanitaria Locale Di BolognaBologna, OlaszországToborzás még nem indult
- Azienda Unita Sanitaria Locale Della RomagnaCesena, OlaszországToborzás még nem indult
- Azienda Ospedaliero - Universitaria di ModenaModena, OlaszországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Azienda Unita Sanitaria Locale Di Bologna
- Trial code
- EU 2025-523065-16-00
- Record updated
- 2026. április 17.
- Original description
To demonstrate that a tailored prescription of antiplatelet drugs can cut the rate of 12-month major cardiovascular events compared to usual careRead full original descriptionShow less
To demonstrate that a tailored prescription of antiplatelet drugs can cut the rate of 12-month major cardiovascular events compared to usual care
Inclusion: Aged ≥18 years old; Males and females; Non-cardioembolic ischemic stroke within the previous 14 days; Starting/prosecuting secondary prevention with single or double anti-platelet therapy after the index stroke; Written informed consent (informed consent can be obtained on incapacitated patients in accordance with national legislation (versions “ex art. 82” of informed consent to study participation and data treatment consent).
Exclusion: Methotrexate used at doses equal to or greater than 15 mg/week. Combination with other potentially myelotoxic drugs. Subjects with or who have had leukopenia, thrombocytopenia, or agranulocytosis; Concurrent need for anticoagulation for any indication; Contraindication to study drugs; Indications to perform carotid revascularization surgery; Active or previous recurrent peptic ulcer and/or gastric/intestinal bleeding, or other types of bleeding such as cerebrovascular hemorrhage; Known hypersensitivity to aspirin, clopidogrel or ticlopidine, or to any of the excipient; Severe renal impairment; Uncontrolled severe cardiac failure; History of asthma induced by the administration of acetylsalicylates or substances with a similar activity, especially nonsteroidal anti-inflammatory drugs; Bleeding diathesis; coagulation disorders such as hemophilia and thrombocytopenia; Severe hepatic impairment; Pregnancy and breastfeeding; WOCBP not using acceptable contraception during the trial period (combined [estrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device [IUD], intrauterine hormone-releasing system [IUS], bilateral tubal occlusion. vasectomised partner, sexual abstinence, progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide).